ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.


Rab8a expression and purification

Recombinant Rab8a expression and purification protocol as used by the Leschziner and Reck-Peterson Labs.


PKC isoforms activate LRRK1 kinase by phosphorylating conserved residues (Ser1064, Ser1074 and Thr1075) within the CORB GTPase domain

Preprint: This study describes how PKC isoforms are able to phosphorylate LRRK1 at 3 sites in a key regulatory domain of the protein (GTPase domain) inducing LRRK1’s kinase activity. Interestingly, this is not seen with the PD-associated LRRK2, suggesting that PKC isoforms do not regulate LRRK2.


Structural Biology of LRRK2 and its Interaction with Microtubules

Review: This review focuses on new insights into the stucture of LRRK2’s cytosolic and microtubule-bound forms and challenges going forward.


LRRK2RCKW Widefield fluorescence microtubule binding assay

This assay uses TMR labeled LRRK2 or LRRK1 RCKW to measure binding to microtubules in vitro


Structural basis for Parkinson’s Disease-linked LRRK2’s binding to microtubules

Preprint: LRRK2 mutations are a common cause of familial PD. In some circumstances, LRRK2 co-localizes with microtubules. The authors report a cryo-electron microscopy structure of the catalytic half of LRRK2, containing its kinase (closed conformation) and GTPase domains, bound to microtubules. Further, they identified amino acids that mediate microtubule binding.